173 related articles for article (PubMed ID: 37851341)
21. PI3K/Akt signalling pathway-associated long noncoding RNA signature predicts the prognosis of laryngeal cancer patients.
Nie Q; Cao H; Yang J; Liu T; Wang B
Sci Rep; 2023 Sep; 13(1):14764. PubMed ID: 37679508
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
Lin A; Gu T; Hu X; Zhang J; Luo P
J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
[TBL] [Abstract][Full Text] [Related]
23. SRC-3/TRAF4 facilitates ovarian cancer development by activating the PI3K/AKT signaling pathway.
Wang Y; Luo X; Wu N; Liao Q; Wang J
Med Oncol; 2023 Jan; 40(2):76. PubMed ID: 36625999
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
Song Y; Qu H
BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
[TBL] [Abstract][Full Text] [Related]
25. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
[TBL] [Abstract][Full Text] [Related]
26. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract][Full Text] [Related]
27. Identification of immunity- and ferroptosis-related genes for predicting the prognosis of serous ovarian cancer.
Yuan X; Zhou Q; Zhang F; Zheng W; Liu H; Chen A; Tao Y
Gene; 2022 Sep; 838():146701. PubMed ID: 35777713
[TBL] [Abstract][Full Text] [Related]
28. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.
Zhao S; Zhang X; Gao F; Chi H; Zhang J; Xia Z; Cheng C; Liu J
Front Endocrinol (Lausanne); 2023; 14():1145797. PubMed ID: 36950684
[TBL] [Abstract][Full Text] [Related]
29. Identification of vitamin D-related signature for predicting the clinical outcome and immunotherapy response in hepatocellular carcinoma.
Wang T; Han L; Xu J; Guo B
Medicine (Baltimore); 2024 May; 103(19):e37998. PubMed ID: 38728505
[TBL] [Abstract][Full Text] [Related]
30. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.
Gasparri ML; Besharat ZM; Farooqi AA; Khalid S; Taghavi K; Besharat RA; Sabato C; Papadia A; Panici PB; Mueller MD; Ferretti E
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2313-2318. PubMed ID: 30109500
[TBL] [Abstract][Full Text] [Related]
31. A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses.
Li J; Qiao H; Wu F; Sun S; Feng C; Li C; Yan W; Lv W; Wu H; Liu M; Chen X; Liu X; Wang W; Cai Y; Zhang Y; Zhou Z; Zhang Y; Zhang S
Front Immunol; 2022; 13():998140. PubMed ID: 36275774
[TBL] [Abstract][Full Text] [Related]
32. Identification and validation of a gene-based signature reveals SLC25A10 as a novel prognostic indicator for patients with ovarian cancer.
Li QJ; Wang J; Jiang J; Lin B
J Ovarian Res; 2022 Sep; 15(1):106. PubMed ID: 36114504
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
34. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
35. miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway.
Wu H; Liu J; Zhang Y; Li Q; Wang Q; Gu Z
Clin Transl Oncol; 2021 Feb; 23(2):257-264. PubMed ID: 32524269
[TBL] [Abstract][Full Text] [Related]
36. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
[TBL] [Abstract][Full Text] [Related]
37. A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer.
Luo Y; Ye Y; Chen Y; Zhang C; Sun Y; Wang C; Ou J
Front Immunol; 2023; 14():1140993. PubMed ID: 36993976
[TBL] [Abstract][Full Text] [Related]
38. Upregulated microRNA-15b alleviates ovarian cancer through inhitbition of the PI3K/Akt pathway by targeting LPAR3.
Li GC; Qin XL; Song HH; Li YN; Qiu YY; Cui SC; Wang YS; Wang H; Gong JL
J Cell Physiol; 2019 Dec; 234(12):22331-22342. PubMed ID: 31140597
[TBL] [Abstract][Full Text] [Related]
39. CT-based machine learning radiomics predicts CCR5 expression level and survival in ovarian cancer.
Wan S; Zhou T; Che R; Li Y; Peng J; Wu Y; Gu S; Cheng J; Hua X
J Ovarian Res; 2023 Jan; 16(1):1. PubMed ID: 36597144
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
